Tandem Diabetes Care reported second quarter 2026 financial results with worldwide sales of $254.6 million, a 6% increase from the prior year period. Gross margin expanded to 57%, up 460 basis points, while the company shipped more than 33,000 pumps globally. The firm reaffirmed its full-year 2026 sales guidance of $1.065 billion to $1.085 billion and updated non-cash charge estimates downward to approximately $85 million. Strategic developments included an FDA submission for Tandem Mobi tubeless capability, regulatory clearances for Control-IQ+ technology in pregnancy and type 2 diabetes, and expanded sensor compatibility with Dexcom G7 and Abbott FreeStyle Libre 3 Plus. The company operates in the medical device industry, specifically manufacturing automated insulin delivery systems for diabetes management.